A Clinical Study to Evaluate the Efficacy and Safety of Tukhm-I Kahu in the Management of Zaght Al-Dam Qawīlāzimī (Essential Hypertension)

Abstract

Aim of this study is to assess the efficacy of Tukhm-ikahu in Zaght al-Dam Qawī Lāzimī (Essential Hypertension) in comparison to Amlodipine (5 mg) tablet. Randomized, standard controlled clinical study was carried out. Patients of high blood pressure (n = 60) with age 35 to 55 years, with Stage-I Hypertension according to JNC 7 (Systolic BP 140-159 and Diastolic BP 90-99 mmHg) were randomized into study; tukhm-ikahu and control; amlodipine (5 mg) groups by block randomization method. Patients with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg, Secondary Hypertension, Pregnant and Lactating women, Obese subjects-BMI > 30, Drug Addicts and Alcoholics were excluded from the study. Study group patients were given 5 gm of powder of tukhm-ikahu twice daily and those of control group Amlodipine 5 mg once daily. Duration of treatment was 6 weeks. Significant difference between Tukhm-ikahu and amlodipine was observed regarding improvement in headache (86.7% vs. 60%), P-value 0.039, vertigo (93.3% vs. 66.7%), P-value 0.021 and sleeplessness (96.67% vs. 73.3%), P-value 0.010. No significant difference was observed between the two regarding reduction in systolic and diastolic pressure at end point of study (P-value 0.675 and 0.552 respectively). No significant difference between the two was recorded regarding palpitation, laziness, anxiety, breathlessness, pulse rate, respiratory rate and temperature; P-value 0.080, 0.299, 0.748, 0.960, 0.858, 0.858 and 0.233 respectively. Tukhm-ikahu possesses efficiency and potency towards treating the high blood pressure and managing the symptoms linked with it.